Navigation Links
Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
Date:5/20/2008

WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- A new 12-week study(2) examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT(R) (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol(2) in treating mild to moderate persistent asthma in children ages 6 to 15 years old(2) who were previously treated with an inhaled corticosteroid (ICS).(2) Of note, the study included efficacy assessments of nighttime symptoms, nighttime rescue medication use and rescue medication-free days in patients taking SYMBICORT compared to those taking formoterol dry powder inhaler (DPI) or budesonide pressurized metered-dose inhaler (pMDI). Results were presented today at the International Conference of the American Thoracic Society held in Toronto, Canada, May 16-21, 2008.

"Children with asthma, who are not adequately controlled by ICS therapy, may have their sleep affected by asthma symptoms,"(6) said Kathy Lampl, MD, Director, Clinical Research, AstraZeneca. "Combination therapy with inhaled ICS and LABA is one of the recommended regimens for children who have moderate to severe persistent asthma or are not controlled with ICS therapy alone, according to the NIH Guidelines."(7)

AstraZeneca (NYSE: AZN) anticipates filing a supplemental new drug application with the Food and Drug Administration for the pediatric indication of SYMBICORT in the first half of 2008.

About the Study (Abstracts #K66 and K67)

The safety profile and efficacy measures of SYMBICORT were assessed during a 12-week randomized, double-blind, active-controlled study that evaluated 411 children ages 6 to 15 years old with mild to moderate persistent asthma(1,2) previously treated with ICS therapy.(1,2) After a two-week period during which patients discontinued their current asthma medications and received two inhalations twice-daily of budesonide pMDI 40 micrograms (mcg), 128 patients(1,2) were randomized to receive treatment with SYMBICORT pMDI 40/4.5 mcg two inhalations twice-daily, 145(1,2) were randomized to receive budesonide pMDI 40 mcg two inhalations twice-daily, and 138(1,2) were randomized to receive formoterol DPI 4.5 mcg two inhalations twice-daily.(1,2)

The study assessed changes in predose AM and PM peak expiratory flow (PEF),(1) which measures the maximum flow of air a person can blow out during a forced breath (the maximum flow achieved during forced expiration),(3) and predose forced expiratory volume in one second (FEV1),(1) which quantifies how much air a person can exhale during a forced breath in the first second of exhalation.(4) In addition, patients and caregivers were instructed to use an electronic diary twice a day to record asthma symptom scores on a scale of 0 to 3 (0=none; 3=severe), nighttime symptoms due to asthma and nighttime rescue medication use.(1) Safety assessments included reported adverse events, electrocardiograms (ECG), clinical chemistry and vital signs.(2)

Results revealed significantly greater improvements from baseline to the average over the treatment period in predose AM and PM PEF for SYMBICORT (23.6 +/- 32.6 and 19.6 +/- 28.4) compared with its mono-components, budesonide (8.0 +/- 26.7 and 6.4 +/- 25.0 L/min) and formoterol (8.6 +/- 30.3 and 6.9 +/- 29.0 L/min).(1) SYMBICORT also demonstrated significantly greater improvements (p<0.05) in predose and postdose FEV1 compared with budesonide.(1) Significant improvements in asthma control as assessed by nighttime symptoms (p<0.05), nighttime rescue medication use (p<0.05) and rescue medication-free days (p<0.05) were reported for patients taking SYMBICORT compared to those taking formoterol.(1) Improvements in nighttime asthma symptom scores and nighttime rescue medication use were similar between patients taking SYMBICORT and those taking budesonide.(1)

Results also showed that SYMBICORT was well tolerated for 12 weeks with a safety profile similar to its mono-components, budesonide and formoterol.(2) The percentage of patients reporting any adverse events, regardless of treatment, was similar for SYMBICORT (70.3%), budesonide (63.4%) and formoterol (70.3%).(2) Most adverse events reported were of mild or moderate intensity and did not lead to discontinuation.(2) Drug-related adverse events for all treatment groups were SYMBICORT (3.1%); budesonide (3.4%); and formoterol (6.5%).(2) No drug-related events led to the discontinuation of SYMBICORT.(2) The most common drug-related adverse events reported were asthma related adverse events, headache, insomnia and cough.(2)

About SYMBICORT

SYMBICORT is a combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older.(5) Administered twice daily, SYMBICORT is a combination of two proven asthma medications -- budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA).(5) SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.(5)

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in greater than or equal to 5 percent of patients, regardless of relationship to treatment, including nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort.

For full Prescribing Information, please visit http://www.MySYMBICORT.com

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information visit http://www.astrazeneca-us.com.

References

1. Murphy, K.R., Pearlman, D.S., Uryniak, T., O'Brien, C.D., Mezzanotte,

W.S. Efficacy of Budesonide/Formoterol Pressurized Metered-Dose Inhaler

(BUD/FM pMDI) in Children With Asthma Previously Treated With Inhaled

Corticosteroids (ICSs) [poster]. American Thoracic Society, May 16-21,

2008, Toronto. Abstract #K66.

2. Pearlman, D.S., Murphy, K.R., Uryniak, T., O'Brien, C.D., Mezzanotte,

W.S. Safety of Budesonide/Formoterol Pressurized Metered-Dose Inhaler

(BUD/FM pMDI) in Children With Asthma Previously Treated With Inhaled

Corticosteroids (ICSs) [poster]. American Thoracic Society, May 16-221,

2008, Toronto. Abstract #K67.

3. Peak Flow Meters. Asthma and Allergy Foundation of America. Retrieved

on 25 April 2008. http://www.aafa.org/display.cfm?id=8&sub=16&cont=62

4. Know Your Asthma Numbers! Asthma and Allergy Foundation of America.

Retrieved on 25 April 2008.

http://www.aafa.org/display.cfm?id=8&sub=16&cont=586

5. Symbicort Prescribing Information.

6. Vargas PA, et al. Annals of Allergy Asthma and Immunology

2006;96(6):787-93.

7. National Asthma Education and Prevention Program. NIH/NHLBI.

Publication Number 08-4051, 2007. Available at

http://www.nhlbi.nih.gov/guidelines/asthma.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
3. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
4. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
5. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
6. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
7. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
8. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
9. Amikacin Inhale Shows Promising Results in Phase II Study
10. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
11. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):